Close Menu

NEW YORK — The US Food and Drug Administration on Monday granted Emergency Use Authorization for a SARS-CoV-2 antibody test developed by Swedish Thermo Fisher Scientific subsidiary Phadia.

The EliA SARS-CoV-2-Sp1 IgG Test is a fluoro-enzyme immunoassay designed for the qualitative and semi-quantitative detection of immunoglobulin G against SARS-CoV-2 in serum and plasma. It runs on the Phadia 250 analyzer with first results available in two hours, according to the company.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.